Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Recurrent Head and Neck Carcinoma Clinical Trial

Official title:

Phase I Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02474368
• Other study ID #: 15-183
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: November 2015
• Est. completion date: June 2024

Study information

• Verified date: April 2024
• Source: Dana-Farber Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study seeks to gain new knowledge about the addition of a carefully targeted "boost" dose of radiation as a possible treatment for recurrent or metastatic head or neck cancer. The name of the study intervention involved in this study is stereotactic body radiotherapy, which is a way of delivering radiation in a more precisely targeted way and with a higher dose than conventional radiotherapy.

Description:

This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied. Stereotactic body radiation was developed as imaging and treatment capabilities on radiation treatment machines became more accurate and more precise. Like standard radiation therapy, stereotactic body radiation kills tumor cells by causing small breaks in the DNA of these cells. In this research study, the investigators are looking for the highest dose of the stereotactic radiation that can be given safely either alone, or as a 'boost dose' in combination with standard radiation and chemotherapy. Because stereotactic radiation is so precise, the investigators are testing whether it can be used to increase the dose to the primary tumor without significantly increasing the side effects; the goal is to improve the likelihood of killing the tumor and, in some cases, to complete the course of radiation in a shorter amount of time.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 21
• Est. completion date: June 2024
• Est. primary completion date: January 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants must meet the following criteria on screening examination to be eligible

to participate in the study:

• All cohorts:
• Participants must have a pathologic cancer diagnosis.
• No other active malignancy within the past 2 years, except for non-melanoma skin cancers or carcinoma in situ of the cervix.
• Only patients 18 years and older are eligible. There is no upper age limit but the patients must be able to medically tolerate the regimen. Adverse event data are currently unavailable on the use of SBRT for participants < 18 years of age, and thus children are excluded from this study.
• Eastern Cooperative Oncology Group (ECOG) performance status =2 (see Appendix A).
• Ability to understand and the willingness to sign a written informed consent document
• Cohort 1 (reirradiation in patients with head and neck cancers with gross unresectable

disease):

• History of radiation to the head and neck area (defined as above the clavicles) greater than 6 months previous
• Pathologically proven recurrent disease or a second primary (squamous cell carcinoma of the head and neck, nasopharyngeal cancer, salivary gland cancer, or thyroid cancer) within the head and neck region, deemed to be unresectable or resected with gross residual disease remaining (determined by either operative/pathology report or post-surgical imaging)
• Participants must have normal organ and marrow function as defined below:
• Leukocytes = 3,000/mcL (microliter)
• Absolute neutrophil count > ?1,500/mcL (microliter)
• Platelets =100,000/mcL (microliter)
• Total bilirubin within normal institutional limits
• aspartate aminotransferase (AST (SGOT))/alanine aminotransferase (ALT (SGPT)) = 2.5 x institutional upper limit of normal
• Creatinine < 2 x upper limit of normal (ULN) or creatinine clearance =45 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal
• Cohort 2 (patients with metastatic disease with targetable lesions within the head and

neck):

• Pathologically proven solid tumor (lymphomas excluded) with evidence of metastatic disease (including nodal disease)
• Measurable disease within the head and neck region, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as =10 mm and < 60 mm with neck CT scan. See section 10 for the evaluation of measurable disease.

Exclusion Criteria:

• Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.
• SBRT target size > 6 cm in maximum diameter (or greater than 100 cc in volume).
• Participants may not be receiving any other study agents.
• Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant women are excluded from this study because radiotherapy has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with SBRT, breastfeeding should be discontinued if the mother is treated with SBRT.
• Individuals with a history of a different malignancy are ineligible except for the following circumstances: if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy; or if diagnosed and treated within the past 2 years for cervical cancer in situ or basal cell or squamous cell carcinoma of the skin.
• HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for interaction between conventional radiotherapy, SBRT and antiretroviral medications. In addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
• Patients who are planned to receive the following medications:
• Granulocyte stimulating factor (G-CSF)
• Bevacizumab
• Cyclosporine
• Anti-tumor necrosis factor agents
• Amifostine

Related Conditions & MeSH terms

• Head and Neck Cancer Metastatic
• Head and Neck Neoplasms
• Head or Neck Cancer
• Neoplasm Metastasis
• Recurrence
• Recurrent Head and Neck Carcinoma

Intervention

Radiation:
• Intensity Modulated Radiation Therapy (IMRT)

Drug:
• Cisplatin

Radiation:
• Stereotactic Body Radiotherapy (SBRT)

Locations

Country	Name	City	State
United States	Dana-Farber Cancer Institute	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose of stereotactic body radiotherapy treatment (SBRT) when given as a boost in combination with cisplatin and intensity modulated radiation therapy (IMRT)	Cohort 1: patients who have received prior radiation in the head and neck and currently have gross unresectable disease;	1 Year
Primary	Maximum tolerated dose of stereotactic body radiotherapy treatment (SBRT) when given for disease metastatic to the head and neck	Cohort 2: Patients with metastatic disease with targetable lesions within the head and neck.	1 year
Secondary	Number of Participants with Adverse Events	Adverse events observed will be summarized in terms of type (organ affected or laboratory determination), severity (by National Cancer Institute, Common Toxicity Criteria for Adverse Effects - CTCAE v4 and nadir or maximum values for the laboratory measures), time of onset (i.e. course number), duration, and reversibility or outcome. Tables will be created to summarize these toxicities and side effects by dose and by course.	1 Year
Secondary	Local Control Rate	Computed tomography (CT) and Positron emission tomography (PET) will be used to assess disease control within the field receiving radiation.	1 Year
Secondary	Regional Control Rate	Computed tomography (CT) and Positron emission tomography (PET) will be used to assess disease control within the head and neck region.	1 Year
Secondary	Progression Free Survival using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1	Progression free survival will be summarized with Kaplan-Meier plots to describe the outcome of patients treated on this protocol. The median progression free survival time will be estimated using standard life table methods.	1 year
Secondary	Level of circulating activated T cells as an immune correlate of stereotactic treatment	This will evaluate circulating immune cells before and after treatment and gene expression analysis focusing on delineating the immune components and immunologic milieu within the tumor before therapy.	1 Year
Secondary	Patient reported physical function before and after treatment	This will investigate changes in patient reported quality of life after treatment using the validated University of Washington Quality of Life Questionnaire (UW-QOL v4) composite score for physical function and comparing results obtained before and after treatment.	1 year
Secondary	Patient reported social function before and after treatment	This will investigate changes in patient reported quality of life after treatment using the validated University of Washington Quality of Life Questionnaire (UW-QOL v4) composite score for social function and comparing results obtained before and after treatment.	1 year